QUECTEL
21.3.2024 10:01:30 CET | Business Wire | Press release
Quectel, a global IoT solutions provider, and The Things Industries, a global leader in LoRaWAN® Internet of Things (IoT) solutions, today announces a partnership that ensures the Quectel KG200Z LoRaWAN module, comes integrated with "Works with The Things Stack" and "Secured by The Things Stack" certifications, providing users with a robust and secure LoRaWAN solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321235728/en/
Quectel and The Things Industries announce partnership to boost module service management through LoRaWAN integration (Graphic: Business Wire)
The Quectel KG200Z module harnesses the power of the STM32WL by STMicroelectronics, offering exceptional performance for long-range, low-power applications. It operates within the LoRa high-frequency band, spanning from 862 MHz to 928 MHz, and incorporates advanced AES hardware encryption for enhanced security. One of the standout features of the KG200Z is its compact profile, measuring just 12.0 mm × 12.0 mm × 1.8 mm, and its LGA form package. This design ensures seamless integration into size-constrained applications while maintaining reliable connectivity.
“Quectel is committed to delivering the most reliable and secure IoT solutions to our customers, and our partnership with The Things Industries is a testament to this promise,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “By combining our KG200Z LoRaWAN module with Quectel’s best-in-classs product security approach with 'Works with The Things Stack' and 'Secured by The Things Stack' certifications, we are not just offering a product; we are providing a comprehensive solution that meets the highest standards of connectivity and security. This collaboration reflects our dedication to innovation and excellence and working with key ecosystem partners to provide best-in-class solutions. ”
Through the collaboration with The Things Industries, Quectel customers are now able to use the KG200Z module in their device design and build, while running additional services through The Things Industries. This partnership empowers users to fully control the end-to-end encryption and key management while leveraging Quectel's decades-long expertise in module capabilities.
Wienke Giezeman, CEO of The Things Industries, commented, "With this partnership, users of the Quectel LoRaWAN module can fully integrate end-to-end encryption and key management in-house, while benefiting from the extensive experience and capabilities that Quectel's modules offer."
Quectel’s IoT modules are developed with security at the core. From product architecture to firmware/software development, Quectel incorporates leading industry practices and standards, mitigating potential vulnerabilities with third party independent test houses and have incorporated security practices like generating SBOMs and VEX files as well as performing firmware binary analysis into the entire software development lifecycle.
Quectel provides a range of antennas alongside the KG200Z module enabling developers and device manufacturers to purchase module and antennas at the same time, streamlining the process and reducing cost and time to market.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
About The Things Industries
The Things Industries is the world’s leading provider of managed and on-premises LoRaWAN network servers, supporting more than 1.5M LoRaWAN devices across the world. As a product leader, it delivers the most feature-complete LoRaWAN network management core and a managed platform at scale.
For more information about the Quectel KG200Z LoRaWAN module, please refer to the data sheet available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321235728/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom